Analyst Consensus ?
ConsensusHold23 ratings
Bullish1356.5%
Neutral730.4%
Bearish313.1%
Roper Technologies, Inc. · ROP · FY2026 Q2 · Calendar Q3 2026
Roper Technologies Beats Q2 Estimates, Raises Guidance on AI Momentum and Strong Cash Flow
Roper Technologies delivered a Q2 beat with revenue of $2.1 billion (+9% YoY) and EPS of $5.38, edging consensus on both top and bottom lines. The company raised full-year guidance, reflecting strong first-half performance and accelerating AI/agentic product deployments across its vertical software portfolio. Capital allocation remains a focal point, with $3.2 billion in year-to-date share repurchases and a $5 billion+ M&A pipeline expected to deploy over the next 12-18 months. The Indicor divestiture to AMETEK adds approximately $1.2 billion in net proceeds, further augmenting deployment flexibility. The stock responded strongly, with an abnormal return of +6.7% on the report day and subsequent drift of nearly +15%, suggesting the market endorsed both the operating results and the capital deployment strategy.
Reported Before market openNASDAQTechnology
$41.18B market cap
100quality score
Company context
Snapshot as of publicationRoper Technologies, Inc., established in 1981 and based in Sarasota, Florida (formerly known as Roper Industries, Inc. until 2015), operates as a diversified technology company. It specializes in developing and delivering advanced software solutions alongside highly engineered products for a wide range of industries. Its extensive software portfolio includes enterprise and financial management systems, cloud-based analytics for sectors like insurance and healthcare, campus and supply chain management tools, and specialized applications for areas such as foodservice, visual effects, and data collaboration. Complementing this, Roper designs and manufactures a diverse array of engineered products, encompassing precision testing instruments for materials like rubber and plastic, medical devices (such as ultrasound accessories), flow and control components (including valves, pumps, and meters), automated dispensing and monitoring equipment (like leak detection and vibration monitoring systems), and various sensors for industrial and utility applications.
Earnings scorecard
Reported versus consensus
Reported EPS
$5.38
Consensus $5
EPS surprise
+1.9%
Reported versus consensus
Reported revenue
$2.11B
Consensus $2.10B
Revenue surprise
+0.6%
Reported versus consensus
Earnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$408.07Current
$355Low
$516.08Average
$665High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 30, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| JP Morgan | Underweight | Underweight | Maintain | Jul 29, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Jul 24, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jul 24, 2026 |
| Barclays | Underweight | Underweight | Maintain | Apr 24, 2026 |
| Baird | Outperform | Outperform | Maintain | Apr 24, 2026 |
| Goldman Sachs | Neutral | Neutral | Maintain | Jan 29, 2026 |
| Truist Securities | Buy | Buy | Maintain | Jan 28, 2026 |
| Stifel | Hold | Buy | Downgrade | Jan 28, 2026 |
| Oppenheimer | Perform | Outperform | Downgrade | Jan 28, 2026 |
| Mizuho | Underperform | Underperform | Maintain | Jan 28, 2026 |
| Citigroup | Buy | Buy | Maintain | Jan 28, 2026 |
| Argus Research | Hold | Buy | Downgrade | Jan 28, 2026 |
| Jefferies | Buy | Buy | Maintain | Jan 5, 2026 |
| TD Cowen | Buy | Buy | Maintain | Oct 24, 2025 |
| Raymond James | Strong Buy | Strong Buy | Maintain | Oct 24, 2025 |
| Wolfe Research | Peer Perform | Outperform | Downgrade | Jun 13, 2024 |
| Wells Fargo | Overweight | Overweight | Maintain | Jan 22, 2024 |
| Bernstein | Outperform | Market Perform | Upgrade | May 2, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Jul 26, 2022 |
| Stephens & Co. | Overweight | Overweight | Maintain | Apr 30, 2019 |
| Argus | Buy | Buy | Maintain | Aug 2, 2018 |
| Canaccord Genuity | Hold | Hold | Maintain | Feb 5, 2018 |
| Stifel Nicolaus | Buy | Buy | Maintain | Feb 2, 2016 |
Named analyst price targets
Upside is calculated against the persisted current price $408.07. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| RBC Capital | Deane Dray | $417 | $370.27 | +2.2% | Jul 24, 2026 |
| Robert W. Baird | Analyst unavailable | $480 | $355.12 | +17.6% | Jul 24, 2026 |
| Piper Sandler | Clarke Jeffries | $526 | $355.12 | +28.9% | Jul 24, 2026 |
| Mizuho Securities | Analyst unavailable | $355 | $362.84 | -13.0% | Jul 21, 2026 |
| BMO Capital | Daniel Jester | $393 | $355.94 | -3.7% | Jul 10, 2026 |
| RBC Capital | Analyst unavailable | $407 | $363.76 | -0.3% | Apr 24, 2026 |
| Robert W. Baird | Analyst unavailable | $470 | $363.76 | +15.2% | Apr 24, 2026 |
| Piper Sandler | Analyst unavailable | $540 | $363.76 | +32.3% | Apr 24, 2026 |
| Barclays | Analyst unavailable | $373 | $363.76 | -8.6% | Apr 24, 2026 |
| Goldman Sachs | Analyst unavailable | $440 | $360.37 | +7.8% | Jan 29, 2026 |
| RBC Capital | Analyst unavailable | $398 | $360.66 | -2.5% | Jan 28, 2026 |
| Mizuho Securities | Analyst unavailable | $365 | $360.98 | -10.6% | Jan 28, 2026 |
| Robert W. Baird | Analyst unavailable | $550 | $358.34 | +34.8% | Jan 28, 2026 |
| Jefferies | Analyst unavailable | $500 | $369.27 | +22.5% | Jan 28, 2026 |
| Barclays | Analyst unavailable | $409 | $369.27 | +0.2% | Jan 28, 2026 |
| Stifel Nicolaus | Analyst unavailable | $385 | $369.27 | -5.7% | Jan 27, 2026 |
| Truist Financial | Terry Tillman | $550 | $369.27 | +34.8% | Jan 27, 2026 |
| Melius Research | Scott Davis | $479 | $355.89 | +17.4% | Jan 27, 2026 |
| Oppenheimer | Analyst unavailable | $525 | $407.48 | +28.7% | Jan 23, 2026 |
| Piper Sandler | Clarke Jeffries | $530 | $432.39 | +29.9% | Jan 13, 2026 |
| Jefferies | Analyst unavailable | $600 | $430.77 | +47.0% | Jan 5, 2026 |
| Mizuho Securities | Analyst unavailable | $419 | $434.54 | +2.7% | Jan 5, 2026 |
| Barclays | Analyst unavailable | $475 | $445.89 | +16.4% | Dec 4, 2025 |
| Piper Sandler | Clarke Jeffries | $600 | $444.78 | +47.0% | Nov 19, 2025 |
| Barclays | Analyst unavailable | $506 | $470.18 | +24.0% | Oct 27, 2025 |
| RBC Capital | Analyst unavailable | $539 | $478.8 | +32.1% | Oct 27, 2025 |
| Truist Financial | Analyst unavailable | $650 | $479.85 | +59.3% | Oct 24, 2025 |
| Stifel Nicolaus | Analyst unavailable | $550 | $479.96 | +34.8% | Oct 24, 2025 |
| RBC Capital | Deane Dray | $644 | $479.96 | +57.8% | Oct 24, 2025 |
| Robert W. Baird | Analyst unavailable | $592 | $479.96 | +45.1% | Oct 24, 2025 |
| Raymond James | Brian Gesuale | $575 | $479.51 | +40.9% | Oct 24, 2025 |
| Jefferies | Analyst unavailable | $650 | $479.96 | +59.3% | Oct 23, 2025 |
| Oppenheimer | Ken Wong | $570 | $479.96 | +39.7% | Oct 23, 2025 |
| Mizuho Securities | Brett Linzey | $510 | $500.08 | +25.0% | Oct 17, 2025 |
| Barclays | Julian Mitchell | $550 | $498.69 | +34.8% | Oct 1, 2025 |
| Mizuho Securities | Brett Linzey | $600 | $582.88 | +47.0% | May 16, 2025 |
| Oppenheimer | Christopher Glynn | $640 | $557.7 | +56.8% | Apr 28, 2025 |
| Stifel Nicolaus | Analyst unavailable | $685 | $582.71 | +67.9% | Mar 26, 2025 |
| Robert W. Baird | Joe Vruwink | $665 | $575.65 | +63.0% | Jan 31, 2025 |
| Truist Financial | Terry Tillman | $665 | $542.94 | +63.0% | Oct 24, 2024 |
| Robert W. Baird | Richard Eastman | $652 | $542.94 | +59.8% | Oct 24, 2024 |
| RBC Capital | Deane Dray | $666 | $542.94 | +63.2% | Oct 24, 2024 |
| Robert W. Baird | Joe Vruwink | $635 | $531.97 | +55.6% | Jul 25, 2024 |
| Barclays | Julian Mitchell | $625 | $550.47 | +53.2% | Jul 10, 2024 |
| Argus Research | John Eade | $575 | $511.46 | +40.9% | Apr 30, 2024 |
| Wolfe Research | Brad Hewitt | $625 | $543.01 | +53.2% | Apr 8, 2024 |
| Oppenheimer | Christopher Glynn | $650 | $556.38 | +59.3% | Mar 22, 2024 |
| Goldman Sachs | Analyst unavailable | $468 | $429.25 | +14.7% | Dec 15, 2022 |
| RBC Capital | Analyst unavailable | $565 | $472.01 | +38.5% | Apr 27, 2022 |
| Cowen & Co. | Joseph C Giordano | $520 | $487.88 | +27.4% | Jul 26, 2021 |
| Oppenheimer | Christopher Glynn | $560 | $494.71 | +37.2% | Jul 23, 2021 |
Track every rating change on ROP the moment it posts. Free to start.
Start freeMarket reaction
prior-close to event-session close
Stock move
+5.5%
Event window
SPY move
-1.2%
Same window
Abnormal move
+6.7%
Stock minus SPY
Volume
1.5×
Versus trailing sessions
Subsequent drift
+14.9%
Up to 20 sessions
ROPSPY benchmark
Follow ROP with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Compared to Q1, revenue growth moderated from 11% to 9% YoY, but the company still raised full-year guidance for both revenue (to >8% total growth) and DEPS (to $22.15-$22.30, up from $21.80-$22.05). AI product cadence accelerated, with Vertafore launching six AI agent SKUs and Procare's Room Runner achieving 20% customer engagement within four hours of launch. The Indicor instrumentation divestiture to AMETEK was announced, generating approximately $1.2 billion in after-tax proceeds. Share repurchases intensified to $3.2 billion year-to-date, representing roughly 8% of shares outstanding. TEP segment margins faced pressure from input-cost inflation, though management expects improvement in the second half.
Guidance delta
Full-year revenue growth guidance raised to above 8% total growth. Full-year DEPS guidance raised to $22.15-$22.30, up from the prior $21.80-$22.05 range issued after Q1.
Key takeaways
- Q2 revenue of $2.1 billion (+9% YoY) and EPS of $5.38 beat consensus estimates of $2.095 billion and $5.28, respectively.
- Free cash flow grew 11% to $447 million, with EBITDA of $815 million at a 38.6% margin.
- Full-year guidance raised to >8% revenue growth and DEPS of $22.15-$22.30.
- AI and agentic product cadence accelerated across Vertafore, DAT, SoftWriters, Procare, and CentralReach.
- Indicor divestiture to AMETEK yields approximately $1.2 billion in net proceeds, adding to $5 billion+ M&A deployment capacity.
- Share repurchases of $3.2 billion year-to-date represent roughly 8% of shares outstanding.
Management priorities
- Accelerate launch of additional AI and agentic SKUs across the vertical software portfolio.
- Continue cloud-first migrations for legacy on-premise solutions.
- Deploy $5 billion+ in strategic acquisitions over the next 12-18 months as the M&A market is expected to break loose.
- Maintain disciplined capital allocation across share repurchases, debt reduction, and selective M&A.
- Expand the AI accelerator team to increase product velocity and build reusable patterns across operating companies.
Sources
- Earnings call transcript and parsed analysis · 2026-07-23T17:04:53.049252+00:00
- FN2 earnings calendar · 2026-07-30T01:23:13.872335+00:00
- Polygon adjusted daily market bars · 2026-07-30T06:01:26.310327+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-30T06:01:26.307785+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.